QuidelOrtho Corporation — Form 8-K Summary
Business Context and Reporting Period
QuidelOrtho Corporation filed a Form 8-K dated April 25, 2024, reporting entry into Amendment No. 2 to its existing credit agreement. The report was signed on April 29, 2024. The filing does not report quarterly operating results or provide a financial reporting-period update.
Material Financing Changes
On April 25, 2024, QuidelOrtho entered into Amendment No. 2 with participating lenders and Bank of America, N.A., as administrative agent. The amendment modifies the May 27, 2022 credit agreement, as previously amended in August 2022 and September 2023.
| Applicable fiscal-quarter period | Maximum consolidated leverage ratio |
|---|---|
| On or prior to June 30, 2023 | 4.50 to 1.00 |
| After June 30, 2023 through June 30, 2024 | 4.00 to 1.00 |
| After June 30, 2024 through December 31, 2024 | 4.25 to 1.00 |
| After December 31, 2024 through June 30, 2025 | 4.00 to 1.00 |
| Each fiscal quarter after June 30, 2025 | 3.75 to 1.00 |
The amendment also makes clarifying changes to certain credit agreement covenants. The filing does not state the company’s current leverage ratio, borrowing capacity, interest rates, outstanding debt, liquidity, or covenant compliance status.
Changes Versus the Prior Comparable Period
The principal change is a revision to the maximum consolidated leverage-ratio requirements, including a temporary increase to 4.25 to 1.00 for fiscal quarters after June 30, 2024 through December 31, 2024, followed by progressively tighter limits. No comparable-period revenue, profit, cash flow, margin, or balance-sheet data is included.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no earnings guidance or operating outlook. The amended leverage requirements indicate ongoing lender monitoring of the company’s capital structure and create potential covenant-compliance risk if leverage exceeds the applicable threshold. The filing does not describe defaults, waivers, events of default, liquidity concerns, collateral changes, or other contingencies.
Investor Verification Items
- Review Exhibit 10.1 for the complete amendment, including all covenant definitions, testing provisions, lender consents, and other revised terms.
- Verify QuidelOrtho’s reported consolidated leverage ratio and covenant compliance in subsequent periodic filings.
- Confirm total debt, maturity dates, available revolver capacity, interest rates, and liquidity position.
- Assess the effect of the tighter 3.75-to-1.00 leverage limit beginning after June 30, 2025.
- Determine whether any additional amendments, waivers, defaults, or financing actions were disclosed after this Form 8-K.